BeiGene, Ltd.

BGNE

US07725L1026

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:28:47 12/12/2024 am IST			5-day change	1st Jan Change
184.94 ^USD	-1.36%		-7.29%	+2.33%

10/12	Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading	MT
10/12	BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about BeiGene, Ltd.

Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading	10/12	MT
BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets	10/12	CI
BeiGene, Ltd. Presents at Citi's 2024 Global Healthcare Conference, Dec-05-2024 09:30 AM	05/12
BeiGene, Ltd. and CLL Society Partner to Advance Test Before Treat? Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL	04/12	CI
BeiGene Insider Sold Shares Worth $9,190,570, According to a Recent SEC Filing	02/12	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	29/11	MT
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	29/11	MT
Hong Kong Stocks End Week in Green; Mokingran Jewellery Gains 8% in Debut	29/11	MT
BeiGene's Four Drugs Included in China's Medical Insurance Catalog; Shares Jump 5%	29/11	MT
BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment	27/11	DJ
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	27/11	MT
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data	27/11	MT
BeiGene's Tevimbra Gets Approval From European Commission as Treatment for Cancer Patients	27/11	MT
BeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval	27/11	DJ
European Commission Approves BeiGene?s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer	27/11	CI
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK	21/11	DJ
Labcorp Holdings Finance Chief Glenn Eisenberg to Retire	19/11	MT
Labcorp Holdings Inc. Announces Executive Changes	19/11	CI
Sector Update: Health Care Stocks Advance Pre-Bell Thursday	14/11	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Powell Speech	14/11	MT
BeiGene Proposes Name Change	14/11	MT
BeiGene to Rename as BeOne Medicines	14/11	MT
BeiGene Swings to Loss in Q3; Hong Kong Shares Slide 3%	13/11	MT
Global markets live: Chipotle, Tesla, Boeing, Apple, Moncler...	12/11

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Employees

10,600

Sector

Biotechnology & Medical Research

Calendar

16/12/2024 - Business Update Call

More about the company